Research has now clearly confirmed that tissue repair and functional improvement attributed to mesenchymal stem cell (MSC) therapy is caused primarily through the secretion of natural therapeutic factors. Based on their early identification and deep understanding of this paracrine mechanism, Theratome Bio scientific founders Dr. Keith March MD, PhD, and YanSheng Du PhD, PhD of The Indiana University School of Medicine have investigated the potential use of these natural therapeutic factors to treat disease in humans.
The therapeutic factors secreted by stem cells have been shown to exert multiple beneficial effects including pro-angiogenic, pro-neurogenic, anti-apoptotic, and anti-inflammatory effects.
Theratome Bio is developing a portfolio of therapies derived from adult stem cell secretome. This new class of therapies will harness the healing potential of adult stem cells while addressing therapeutic and practical shortcomings of stem cell therapies. Advantages include defined dose, immediate bioavailability of therapeutic factors, lowered risk of immunogenicity with repetitive dosing, and eliminating the complicated storage and handling associated with cell therapies.
Human trials of Theratome Bio’s lead asset Thera-101 are being planned for 2019.